<?xml version="1.0" encoding="UTF-8"?>
<p>Since the late 2019 when a cluster of pneumonia associated with the emerging novel coronavirus, SARS-CoV-2 was reported in Wuhan, China. Since then, the outbreak has spread rapidly and developed into a global pandemic. At the time the paper was submitted, about 210 countries and territories around the world have reported more than 2.9 million confirmed cases of SARS-CoV-2 including more than 203,289 deaths (
 <ext-link ext-link-type="uri" xlink:href="https://www.worldometers.info/coronavirus/#countries" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.worldometers.info/coronavirus/#countries</ext-link>). Currently, there is no antiviral therapy or vaccine available for human usage. It is urgent to develop some antiviral compounds for the treatment of SARS-CoV-2 infection because of its high infectivity and morbidity and its ability to cause epidemics worldwide. Different compounds, such as remdesivir and chloroquine have been reported to inhibit SARS-CoV-2 replication effectively 
 <italic>in vitro</italic> [
 <xref rid="CIT0001" ref-type="bibr">1</xref>]. The efficacy of these drugs for SARS-CoV-2 is still under investigation by clinical experiments.
</p>
